Skip to content

Clinical Application and Formulation Development of He's Wenshen Ditan Decoction for the Treatment of Polycystic Ovary Syndrome

Clinical Application and Formulation Development of He's Wenshen Ditan Decoction for the Treatment of Polycystic Ovary Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000648
Enrollment
Unknown
Registered
2025-04-06
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Interventions

control group:metformin 500mg bid
experimental group:Wenshen Ditan decotion one dose per day with metformin 500mg bid

Sponsors

The Affiliated Hangzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Patients Diagnosed with Kidney Deficiency and Phlegm-Dampness Type PCOS and Insulin Resistance 2.Women of Reproductive Age Aged 18-40 3.No use of any medications affecting menstruation (e.g. contraceptives hormones or other drugs affecting insulin blood sugar sex hormones and lipid metabolism) or related treatment methods within the past 3 months and no history of abortion 4.Gynecological examination and auxiliary examinations: No organic lesions in internal and external reproductive organs and no other primary diseases 5.Patients who have signed the informed consent form and are willing to bear any potential consequences and risks

Exclusion criteria

Exclusion criteria: 1.Exclusion of patients aged 40 2.Patients with congenital insufficiency in their reproductive system that does not meet the requirements of this study 3.Exclusion of patients with genetically inherited mental disorders 4.Exclusion of patients with organ failure in the liver heart kidneys hematopoietic system etc. 5.Exclusion of patients with special constitutions and a history of severe drug allergies 6.Exclusion of patients who cannot comply with the study protocol 7.Exclusion of patients requiring treatment for other conditions that could affect the study results

Design outcomes

Primary

MeasureTime frame
Comprehensive efficacy evaluation;

Secondary

MeasureTime frame
Basic body temperature;Syndrome Score;Blood insulin level, blood glucose level and HOMA-IR.;Sex hormone level;Serum inflammatory factors;Gene sequencing.;Metabolomics;

Countries

Chian

Contacts

Public ContactQin Zhang

The Affiliated Hangzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University

zhaqin01@163.com13606258580

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026